Large Biopharma Company Engages LexaGene in Statement of Work to Expedite Technology Validation
bdtonline.com
news
2022-10-20 11:47:24

BEVERLY, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., ( OTCQB: LXXGF; TSX-V: LXG ) ('LexaGene' or the 'Company'), an innovative, molecular diagnostics company that has commercialized the MiQLab® System for automated, genetic testing, is pleased to announce that it has signed a statement of work with the same biopharma company that purchased a System last week.Dr. Jack Regan, LexaGene's CEO and Founder stated, 'The technology validation study outlined within the signed statement of work will provide this biopharma company much of the data they need to make future decisions in just a few weeks of time.
